We observed an abnormal increase in glutamate levels in TC-anlotinib-resistant cell lines during early-stage metabolome sequencing, accompanied by an abnormal decrease in LPAR1 levels, as revealed by transcriptome sequencing, both of which were subsequently confirmed in tumor tissues. This evidence concerns the gene LPAR1 and neoplasm.